| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-50 |
| filingDate |
2017-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2019-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102048474-B1 |
| titleOfInvention |
Composition for Inhibiting Tolerance Against Epidermal Growth Factor Receptor Targeting Inhibitor |
| abstract |
The present invention relates to methods of regulating resistance or sensitivity to an Epidermal Growth Factor Receptor (EGFR) target agent through a peptide that specifically binds Neuropilin 1. In addition, resistance or susceptibility to EGFR target agents through a combination of a fusion antibody and an EGFR target agent in which a peptide specifically binding to neuropilin 1 is fused to an EGFR target antibody and a heavy chain constant region of the antibody in which the peptide is fused. It relates to a composition to be adjusted. In addition, a fusion antibody in which a peptide specifically binding to neuropilin 1 according to the present invention is fused to an EGFR target antibody overcomes resistance to the EGFR target antibody in pancreatic cancer. In addition, a fusion antibody in which a peptide specifically binding to neuropilin 1 is fused to an EGFR target antibody overcomes the resistance to the EGFR target antibody even in lung cancer having resistance to the EGFR target antibody. Therefore, through the peptide specifically binding to neuropilin 1 according to the present invention, a high effect can be expected in the treatment of various tumors having resistance to the EGFR target agent. |
| priorityDate |
2016-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |